Efficacy and safety of telitacicept in patients with lupus nephritis: a single-center, real-world retrospective study
Clinical and Experimental Nephrology · 2024
DOI: 10.1007/s10157-024-02501-x ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Experimental Nephrology, 2024. Verfasst von Xiaolu Huang und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology, Zhangzhou Affiliated Hospital of Fujian Medical University, No.59 Shengli West Road, Xiangcheng District, Zhangzhou, 3630…. Hauptthemen laut MEDLINE: Lupus Nephritis. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 17 Literaturangaben. Gefördert von: Qihang Project of Fujian Medical University.
Abstract (Originalsprache)
BACKGROUND: Telitacicept, an innovative drug used for the treatment of systemic lupus erythematosus (SLE), can effectively control disease progression and achieve favorable outcomes. While case reports have mentioned the use of Telitacicept in lupus nephritis (LN) treatment, its safety and efficacy in treating patients with LN have not been explored. Therefore, in this study, we aimed to evaluate the safety and efficacy of Telitacicept in managing patients with LN. METHODS: In a single-center, real-world retrospective study, 30 LN patients with poor response or adverse reactions to conventional glucocorticoids at our Hospital were enrolled to receive Telitacicept. Patients were administered 160 mg of Telitacicept subcutaneously once a week for at least 24 weeks in addition to standard treatment. We assessed the SLE responder index-4 (SRI-4) at the beginning and the end of the treatment period, measured laboratory test indicators at 3, 6, and 9 months, and observed the occurrence of adverse events in these patients. RESULTS: The SRI-4 response rate was 86.67% (n = 26), with a significantly lower systemic lupus erythematosus disease activity index (SLEDAI) score compared to the baseline. Post Telitacicept treatment, glucocorticoid intake of patients with LN significantly reduced from 50 (IQR:40, 51.25) at baseline to 10 (IQR:5,10) at the endpoint (Z = - 6.547, p < 0.001). Patients with LN showed significantly improved urine occult blood levels after Telitacicept therapy. While the complement (C3 and C4) contents increased, immunoglobulins (IgG, IgA and IgM) reduced markedly (p < 0.001). The negative rate of dsDNA reached 26.67% and adverse events were alleviated post treatment. Only two cases of LN-related adverse reactions were reported, including herpes and infectious fever, respectively. Telitacicept primarily serves as an agent for the induction of remission therapy, with an attainment of complete remission rate standing at a commendable 73.3%. CONCLUSIONS: Telitacicept treatment reduced disease severity in patients with LN. The initial clinical trial provided supportive evidence for the effectiveness and safety of Telitacicept as a viable treatment option for LN, allowing a reduction in the daily glucocorticoid intake while maintaining a good safety profile, and improving hypocomplementation in LN management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Rheumatology, Zhangzhou Affiliated Hospital of Fujian Medical University, No.59 Shengli West Road, Xiangcheng District, Zhangzhou, 363000, Fujian Province, China.
- Department of Rheumatology, Zhangzhou Affiliated Hospital of Fujian Medical University, No.59 Shengli West Road, Xiangcheng District, Zhangzhou, 363000, Fujian Province, China. chenghongpu@163.com.
Förderung
- Qihang Project of Fujian Medical University
Zitieren
APA
Huang, X., Lin, F., & Chen, H. (2024). Efficacy and safety of telitacicept in patients with lupus nephritis: a single-center, real-world retrospective study. Clinical and Experimental Nephrology. https://doi.org/10.1007/s10157-024-02501-x
Vancouver
Huang X, Lin F, Chen H. Efficacy and safety of telitacicept in patients with lupus nephritis: a single-center, real-world retrospective study. Clinical and Experimental Nephrology. 2024. doi:10.1007/s10157-024-02501-x
BibTeX
@article{Huang2024,
author = {Huang, Xiaolu and Lin, Fuan and Chen, Hongpu},
title = {Efficacy and safety of telitacicept in patients with lupus nephritis: a single-center, real-world retrospective study},
journal = {Clinical and Experimental Nephrology},
year = {2024},
doi = {10.1007/s10157-024-02501-x}
}
EUVIMED